Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Harvard Business School

Last Updated: June 4, 2023

Drug Sales Trends for ESTRIOL/ESTRADIOL (50:50)-LETCO 0.25MG/

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Drug Sales Revenue Trends for ESTRIOL/ESTRADIOL (50:50)-LETCO 0.25MG/
Drug Units Sold Trends for ESTRIOL/ESTRADIOL (50:50)-LETCO 0.25MG/

Annual Sales Revenues and Units Sold for ESTRIOL/ESTRADIOL (50:50)-LETCO 0.25MG/

These sales figures are drawn from a US national survey of drug expenditures
Drug Name Revenues (USD) Units Year
ESTRIOL/ESTRADIOL (50:50)-LETCO 0.25MG/ ⤷  Try a Trial ⤷  Try a Trial 2019
ESTRIOL/ESTRADIOL (50:50)-LETCO 0.25MG/ ⤷  Try a Trial ⤷  Try a Trial 2018
ESTRIOL/ESTRADIOL (50:50)-LETCO 0.25MG/ ⤷  Try a Trial ⤷  Try a Trial 2017
>Drug Name >Revenues (USD) >Units >Year

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:


Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.